What Iksuda Therapeutics does

Iksuda Therapeutics is a clinical-stage biotechnology company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Founded in 2007 as Glythera Ltd and rebranded in 2018, the company is headquartered in Newcastle upon Tyne, UK, with US operations in Boston, MA. Iksuda's pipeline comprises two clinical-stage programs—IKS014 (HER2-directed, Phase 1 dose expansion) and IKS03 (CD19-directed, Phase 1 first patient dosed May 2025)—along with preclinical assets IKS04 (CA242, GI tumors) and IKS073 (B7H3, first ProAlk-containing ADC). Phase 1 IKS014 data have shown a 64% ORR in advanced breast cancer patients and a 50% ORR in pre-treated HER2+ esophageal cancer patients, with a preclinical therapeutic index of 12 versus less than 1.5 for Kadcyla and less than 3 for Enhertu.

The company's technology stack is built on three modular platforms: (1) PermaLink, a proprietary vinyl-pyridine cysteine-specific bioconjugation chemistry delivering market-leading plasma stability; (2) ProAlk, a first-in-class protein alkylating payload class (licensed from the University of Goettingen) offering a novel mechanism of action distinct from tubulin inhibitors and DNA cross-linkers, with MDR resistance and bystander activity; and (3) tumor-selective glucuronide-driven payload activation, clinically validated through IKS014 and CS5001. Iksuda also uses the ConjuAll site-specific homogeneous conjugation platform licensed from LegoChem Biosciences. ADC programs are designed for maximum anti-cancer impact and a wide therapeutic index by combining the optimal binder, linker, and payload for each target.

Iksuda's business model is licensing- and partnership-driven. The company generates non-dilutive capital through platform and program out-licensing (e.g., IKS014 licensed as FS-1502 to Fosun Pharma for Greater China), with development, regulatory, and commercial milestone payments plus royalties. It also raises equity financing (cumulative disclosed funding of approximately $49.2M, including a $47M Series A in June 2021 co-led by Mirae Asset Capital and Celltrion). The company has not yet generated product revenue. Its primary customers are pharmaceutical and biotechnology partners seeking ADC development expertise and licenses, with the end-patient focus being oncology patients with solid tumors and B-cell malignancies who have relapsed on or are refractory to standard of care.

Name

Iksuda Therapeutics

Legal name

Iksuda Therapeutics Limited

Website

https://iksuda.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Iksuda Therapeutics is a clinical-stage UK biotech developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers, leveraging proprietary PermaLink bioconjugation and ProAlk payload platforms. It serves oncology patients with relapsed/refractory solid tumors and B-cell malignancies through licensing partnerships with major pharma.

Ownership category

akta.pro rank

Product category

Antibody-Drug Conjugates (ADC) Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Antibody drug conjugates
• Oncology therapeutics development
• Bioconjugation platforms
• ADC drug development
• Tumor-selective payloads

Headquarters

HQ city

Newcastle Upon Tyne

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. ADC Drug Development & Commercialization: Iksuda is a clinical-stage biotech developing a pipeline of differentiated ADCs for hard-to-treat cancers. The company has not yet generated product revenue. Future revenue is expected from global commercialization of its proprietary ADC pipeline, either independently or through co-development partnerships, targeting hematological and solid tumor indications with high unmet need.
2. Licensing & Partnership Deals: Iksuda generates non-dilutive capital through licensing agreements for its proprietary platforms (PermaLink, ProAlk) and ADC programs. The company has in-licensed programs (IKS03 from LegoChem, IKS014 from LegoChem) and out-licensed regional rights (FS-1502/IKS014 to Fosun Pharma for Greater China). Partnerships include development, regulatory, and commercial milestone payments plus royalties on sales.
3. Equity Financing: The company has raised equity capital to fund R&D and clinical development. Completed a $47M (approx. £34M) Series A financing round in June 2021, co-led by Mirae Asset Capital and Celltrion. Prior seed and venture rounds include £2M in 2012 and £700K in 2013. No public market listing as of the available data.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Iksuda Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. Its pipeline includes clinical-stage programs IKS014 (HER2-directed, Phase 1) and IKS03 (CD19-directed, Phase 1) plus preclinical IKS04 and IKS073, all built on the proprietary PermaLink bioconjugation platform, ProAlk protein alkylating payload class, and tumor-selective glucuronide cleavable linkers. The company commercializes its ADC programs and platforms through global licensing deals and independent clinical development.

Product overview

Iksuda Therapeutics is a clinical-stage biotech company developing a pipeline of class-leading Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers. The company's portfolio includes two clinical-stage ADCs (IKS03 and IKS014), two preclinical programs (IKS04 and IKS073), and an expanding discovery-stage pipeline of ProAlk-ADCs. The ADC platform combines tumor-selective payload activation technology using glucuronide linkers, multiple payload classes (PBD, MMAF, and proprietary ProAlk protein alkylators), and stable bioconjugation platforms (proprietary PermaLink and licensed ConjuAll).

Differentiator

Problem solved

Functional benefit

Products and services

• IKS03 CD19-directed ADC in Phase 1 clinical trials for B-cell malignancies including DLBCL and Mantle Cell Lymphoma, using a tumor-selective glucuronide linker with PBD prodrug payload and showing class-leading therapeutic index (preclinical TI >5 vs. <1 for Zynlonta and <1.2 for Polivy). Licensed-in from LegoChem Biosciences (originally LCB73).
• IKS014 HER2-directed ADC in Phase 1 dose expansion for HER2+ solid tumors including breast, gastric, lung, and esophageal cancers. Uses MMAF payload with glucuronide linker technology for improved safety profile. Licensed-in from LegoChem Biosciences; out-licensed to Fosun Pharma as FS-1502 for Greater China.
• IKS04 CA242 (CanAg)-directed ADC in preclinical/IND-enabling studies for GI tumors including colorectal, pancreatic, gastric, and bladder cancers. Uses ultra-low DAR approach with PBD prodrug payload to improve tumor penetration in high-expression tumors.
• IKS073 B7H3-directed ADC in IND-enabling studies for solid tumors including lung, esophageal, head & neck, colorectal, stomach, breast, and cervix. First ADC to incorporate Iksuda's proprietary ProAlk protein alkylating payload with novel mechanism.
• ProAlk Payload Platform Proprietary first-in-class protein alkylating payload class for ADCs available for licensing to pharma partners. Exerts cell-killing activity through alkylation of cytosolic proteins rather than DNA cross-linking, used in prodrug format with glucuronide triggers for tumor-selective activation. MDR-resistant with potent bystander activity.
• PermaLink Bioconjugation Platform Proprietary ultra-stable cysteine-specific bioconjugation chemistry platform using vinyl-pyridine approach, available for licensing against selected targets of interest. Delivers market-leading ADC plasma stability with minimal DAR decrease over time, and is compatible with a broad range of payloads.

Quantifiable outcome

• IKS014 Phase 1: ORR of 64% in 11 advanced breast cancer patients at doses ≥90 mg/m², including responses in patients previously treated with Enhertu; ORR of 50% in 10 pre-treated HER2+ esophageal cancer patients; clinical benefit rate of 80% in esophageal cancer patients.
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• LegoChem Biosciences (LCB)coreTechnology or Integration · 10 January 2022License and commercialization agreement for LCB's HER2 ADC program (LCB14, now IKS014). Iksuda gained exclusive worldwide rights excluding Greater China and South Korea. Agreement includes development, regulatory, and commercial milestone payments plus royalties on commercial sales. LCB also licensed IKS014 to Fosun Pharma for Greater China.
• University of GoettingencoreTechnology or Integration · 13 October 2020Exclusive worldwide licensing agreement for a novel class of tumor-activated prodrug payloads with protein alkylating cytotoxicity (ProAlk series). Partnership founded on successful collaboration exemplifying the series in ADC formats. The novel protein alkylating mode of action differs from DNA cross-linking, conferring benefits against drug resistance mechanisms.
• LegoChem Biosciences (LCB)coreTechnology or Integration · 18 May 2020Licensing agreement for LCB's anti-CD19 ADC program (LCB73, now IKS03) for B-cell cancers including DLBCL and Burkitt lymphoma. Iksuda gained worldwide rights for development and commercialization. IKS03 delivers a tumor-activated prodrug PBD payload with preclinical data showing best-in-class TI over comparators.
• LegoChem Biosciences (LCB)coreTechnology or Integration · 16 April 2020Multi-target research collaboration and license agreement granting Iksuda access to LCB's next-generation PBD prodrug payload and proprietary linker (ConjuAll platform) for up to three undisclosed targets. Iksuda gained rights to research, develop, and commercialize targeted anti-cancer therapeutics using LCB's technology.
• LegoChem Biosciences (LCB)coreStrategic or Co-development Partner · 16 April 2020Expanded license agreement granting Iksuda access to LCB's next-generation ADC platform technology for up to six targets, supplementing the tumor-activated payloads accessed in the 2020 licensing agreement. The expansion included LCB's new payload technology.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ADC Therapeutics: Clinical-stage ADC biotech developing ADCs for hematologic and solid tumors, with multiple Phase 1/2 programs and a similar pipeline-based business model. Most directly comparable in stage, modality focus, and go-to-market approach.
• Mersana Therapeutics: Clinical-stage ADC biotech with proprietary payload platforms (e.g., Dolasynthen, Immunosynthen) targeting oncology. Closely comparable as a platform-based ADC developer with multiple proprietary payload classes and clinical-stage assets.
• Tubulis: European clinical-stage ADC biotech with proprietary bioconjugation and payload platforms. Highly comparable in technology strategy (proprietary linkers + payloads) and European clinical-stage positioning.
• Heidelberg Pharma: German clinical-stage ADC biotech with a proprietary amanitin-based payload platform (similar to Iksuda's ProAlk in offering a novel payload MoA). Closely comparable as a European platform-based ADC developer pursuing first-in-class payload differentiation.
• Bolt Biotherapeutics: Clinical-stage oncology biotech developing immune-stimulating ADCs. Comparable as a clinical-stage ADC innovator with proprietary platform technology, though focused on immune stimulation rather than cytotoxic payloads.
• Pyxis Oncology: Clinical-stage oncology biotech with ADC and immuno-oncology programs. Comparable as a multi-program clinical-stage ADC developer pursuing novel linker and payload strategies.
• ProfoundBio: Clinical-stage ADC biotech developing ADCs for solid tumors with proprietary conjugation technology. Comparable in clinical-stage ADC focus and platform-based differentiation approach.

Broad incumbents

• ImmunoGen (AbbVie): Pioneer of ADC technology and developer of Kadcyla (where Iksuda CSO Bob Lutz led development). Acquired by AbbVie in 2024. Broad incumbent reference point for ADC platform validation and competitive context.

Regional players

• Innovent Biologics: Chinese biopharmaceutical company with a growing ADC pipeline. Comparable as a Chinese-market ADC developer analogous to Fosun Pharma's regional role with IKS014 (FS-1502).

Others

• WuXi XDC: ADC-focused contract development and manufacturing organization (CDMO). Comparable as an ecosystem participant that supports ADC developers like Iksuda with conjugation and manufacturing services, providing a market context for ADC development economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/iksudat

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iksuda Therapeutics